← Leaderboards
David W Pascual
Montana State University (Bozeman)
$22,231,160
Attributed
$22,231,160
Total exposure
28
Grants
24
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$22,231,160 · 28
By mechanism
R01$16,251,914 · 11
P20$2,065,587 · 7
U54$1,532,734 · 3
R21$1,388,924 · 4
R56$696,375 · 2
S10$295,626 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsOralVaccinesImmunityT-LymphocyteTissuesNoseImmunizationCytokineResponseMucous MembraneAntigensAutoimmune DiseasesPreventArthritisAnimalsImmuneSymptomsLinkLifeIngestionAdjuvantInterferon Type IiLearning
Grant awards (77)
Regulatory Cell Therapy for Sjogrens Syndrome$265,724
R56 · FY2023 · DE · contact PI
Regulatory Cell Therapy for Sjogrens Syndrome$85,026
R56 · FY2023 · DE · contact PI
Naso-oropharyngeal Brucella Infections and Mucosal Immune Protection$376,668
R01 · FY2021 · AI · contact PI
Regulatory Cell Therapy for Sjögren's Syndrome.$362,188
R01 · FY2021 · DE · contact PI
Snodgrassella alvi as an attenuated live vaccine against Neisseria gonorrhoeae$241,873
R21 · FY2021 · AI · contact PI
Mucosal Vaccines for Brucellosis$388,659
R01 · FY2020 · AI · contact PI
Naso-oropharyngeal Brucella Infections and Mucosal Immune Protection$376,886
R01 · FY2020 · AI · contact PI
Regulatory Cell Therapy for Sjögren's Syndrome.$362,188
R01 · FY2020 · DE · contact PI
Mucosal Vaccines for Brucellosis$411,989
R01 · FY2019 · AI · contact PI
Naso-oropharyngeal Brucella Infections and Mucosal Immune Protection$377,094
R01 · FY2019 · AI · contact PI
Regulatory Cell Therapy for Sjögren's Syndrome.$362,188
R01 · FY2019 · DE · contact PI
Mucosal Vaccines for Brucellosis$436,758
R01 · FY2018 · AI · contact PI
Naso-oropharyngeal Brucella Infections and Mucosal Immune Protection$377,292
R01 · FY2018 · AI · contact PI
Regulatory Cell Therapy for Sjögren's Syndrome.$362,188
R01 · FY2018 · DE · contact PI
Naso-oropharyngeal Brucella Infections and Mucosal Immune Protection$377,481
R01 · FY2017 · AI · contact PI
Mucosal Vaccines for Brucellosis$375,000
R01 · FY2017 · AI · contact PI
Regulatory Cell Therapy for Sjögren's Syndrome.$362,188
R01 · FY2017 · DE · contact PI
Fimbriae Countermeasures for Type 1 Diabetes$181,847
R21 · FY2017 · AI · contact PI
Mucosal Vaccines for Brucellosis$27,057
R01 · FY2017 · AI · contact PI
Mucosal Vaccines for Brucellosis$375,000
R01 · FY2016 · AI · contact PI
Sony Cell Sorter SH800 System$295,626
S10 · FY2016 · OD · contact PI
Fimbriae Countermeasures for Type 1 Diabetes$219,615
R21 · FY2016 · AI · contact PI
"Subunit Vaccines for Brucella Pathogens"$363,417
R01 · FY2015 · AI · contact PI
"Subunit Vaccines for Brucella Pathogens"$463,574
R01 · FY2014 · AI · contact PI
"Subunit Vaccines for Brucella Pathogens"$444,037
R01 · FY2013 · AI · contact PI
Mucosal Therapy for Autoimmunity$343,183
R01 · FY2013 · AI · contact PI
"Subunit Vaccines for Brucella Pathogens"$277,196
R01 · FY2012 · AI · contact PI
Mucosal Therapy for Autoimmunity$183,824
R01 · FY2012 · AI · contact PI
Mucosal Therapy for Autoimmunity$165,336
R01 · FY2012 · AI · contact PI
"Subunit Vaccines for Brucella Pathogens"$124,335
R01 · FY2012 · AI · contact PI
"Subunit Vaccines for Brucella Pathogens"$515,532
R01 · FY2011 · AI · contact PI
Mucosal Therapy for Autoimmunity$349,161
R01 · FY2011 · AI · contact PI
"Mechanisms of IL-35 Protection Against Arthritis"$160,000
R21 · FY2011 · AR · contact PI
MT VET COBRE II CORE C: ANIMAL MODELS$126,289
P20 · FY2011 · RR · contact PI
Mucosal Therapy for Autoimmunity$352,688
R01 · FY2010 · AI · contact PI
"Mechanisms of IL-35 Protection Against Arthritis"$200,001
R21 · FY2010 · AR · contact PI
MT VET COBRE II CORE C: ANIMAL MODELS$144,108
P20 · FY2010 · RR · contact PI
Mucosal Immunity Elicited by Salmonella Vaccine Delivery$296,143
R01 · FY2009 · AI · contact PI
DNA Vaccines for Q fever$188,138
U54 · FY2009 · AI · contact PI
Mucosal Therapy for Autoimmunity$178,125
R01 · FY2009 · AI · contact PI
MT VET COBRE CORE D: BIOSAFETY LEVEL 3 CORE$72,078
P20 · FY2009 · RR · contact PI
Mucosal Therapy for Autoimmunity$345,625
R56 · FY2008 · AI · contact PI
DNA Vaccines for Q Fever$302,625
U54 · FY2008 · AI · contact PI
Mucosal Immunity Elicited by Salmonella Vaccine Delivery$296,143
R01 · FY2008 · AI · contact PI
Mucosal Lymphocyte Homing in the Head and Neck$296,143
R01 · FY2008 · AI · contact PI
Novel Vaccine Platform and Adjuvants for Biodefense$189,213
U54 · FY2008 · AI · contact PI
CAM Intervention for Rheumatoid Arthritis$173,338
R21 · FY2008 · AT · contact PI
MT VET COBRE CORE D: BIOSAFETY LEVEL 3 CORE$108,158
P20 · FY2008 · RR · contact PI
DNA Vaccines for Q Fever$344,148
U54 · FY2007 · AI · contact PI
Mucosal Lymphocyte Homing in the Head and Neck$301,878
R01 · FY2007 · AI · contact PI
Mucosal Immunity Elicited by Salmonella Vaccine Delivery$301,878
R01 · FY2007 · AI · contact PI
CAM Intervention for Rheumatoid Arthritis$212,250
R21 · FY2007 · AT · contact PI
MT VET COBRE CORE D: BIOSAFETY LEVEL 3 CORE$115,601
P20 · FY2007 · RR · contact PI
Mucosal Vaccines for Plague$353,538
R01 · FY2006 · AI · contact PI
Mucosal Lymphocyte Homing in the Head and Neck$310,894
R01 · FY2006 · AI · contact PI
MT VET COBRE CORE D: BIOSAFETY LEVEL 3 CORE$282,213
P20 · FY2006 · RR · contact PI
Mucosal Immunity Elicited by Salmonella Vaccine Delivery$276,350
R01 · FY2006 · AI · contact PI
DNA Vaccines for Q Fever$255,542
U54 · FY2006 · AI · contact PI
MT VET COBRE: BIOSAFETY LEVEL 3 CORE$662,075
P20 · FY2005 · RR
Mucosal Vaccines for Plague$351,500
R01 · FY2005 · AI
Mucosal Lymphocyte Homing in the Head and Neck$318,375
R01 · FY2005 · AI
Mucosal Immunity Elicited by Salmonella Vaccine Delivery$283,000
R01 · FY2005 · AI
DNA Vaccines for Q Fever$253,068
U54 · FY2005 · AI
Mucosal Vaccines for Plague$592,717
R01 · FY2004 · AI
MT VET COBRE: BIOSAFETY LEVEL 3 CORE$555,065
P20 · FY2004 · RR
Mucosal Lymphocyte Homing in the Head and Neck$308,000
R01 · FY2004 · AI
TARGETED DNA DELIVERY FOR SALIVARY IGA RESPONSES$208,250
R01 · FY2004 · DE
MUCOSAL TRANSGENE VACCINATION FOR HIV$280,000
R01 · FY2003 · AI
TARGETED DNA DELIVERY FOR SALIVARY IGA RESPONSES$208,250
R01 · FY2003 · DE
MUCOSAL TRANSGENE VACCINATION FOR HIV$280,167
R01 · FY2002 · AI
TARGETED DNA DELIVERY FOR SALIVARY IGA RESPONSES$208,250
R01 · FY2002 · DE
MUCOSAL TRANSGENE VACCINATION FOR HIV$270,875
R01 · FY2001 · AI
MUCOSAL IMMUNITY ELICITED BY SALMONELLA VACCINE DELIVERY$219,754
R01 · FY2001 · AI
TARGETED DNA DELIVERY FOR SALIVARY IGA RESPONSES$208,250
R01 · FY2001 · DE
TARGETED DNA DELIVERY FOR SALIVARY IGA RESPONSES$229,500
R01 · FY2000 · DE
MUCOSAL IMMUNITY ELICITED BY SALMONELLA VACCINE DELIVERY$213,354
R01 · FY2000 · AI
INTRANASAL GENE TRANSFER FOR MUCOSAL VACCINATION$167,473
R01 · FY2000 · AI